| News
Lonza plans to create new jobs at Stücki Park
29.03.2019
Swiss Prime Site is about to create additional office and laboratory space for 1,700 new jobs at Stücki Park in Basel. The chemical specialists Lonza will rent space to hire an additional 250 specialists from 2020.

Stücki Park (img: Florian Lotter)
Stücki Park is being expanded further. Swiss Prime Site has announced in a press release that 190 million Swiss francs will be invested in expanding the existing laboratory and office space. This will see the rental area more than doubled by 33,000 square meters to a total of 60,000 square meters by 2023, thereby creating space for 1,700 new jobs at the site in north Basel.
The chemical specialists Lonza, already an established presence at Stücki Park as anchor tenants, will rent new buildings across a surface area of 8,000 square meters. From the third quarter of 2020, around 250 new specialists will work in the new buildings, “thus further enhancing Basel as a major economic area”, as Prof. Dr. Hanns-Christian Mahler, Head of Lonza Drug Product Services, commented in the press release. “As we continue to grow in Drug Product Services, the new buildings at Stücki Park are ideal for us”, he concluded.
Peter Lehmann, CEO Swiss Prime Site Immobilien, was delighted about Lonza’s expansion, commenting in the press release: “The complete rental of the existing long building and a substantial part of the new building represents a significant milestone for the site, which this project will make considerably more attractive”.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
Clinerion is now part of Citeline
Clinerion has been integrated into New York-based company Citeline. Clinerion plans to expand its portfolio with Citeline’s complementary opportunities with...
Read MoreKUORI developing biodegradable plastics
The Basel-based cleantech company KUORI GmbH develops alternative materials for conventional plastics. The aim is to reduce the accumulation of...
Read MoreCell and gene therapies gain momentum in Basel
Companies specializing in the research and development of innovative cell and gene therapies continue to spring up all around the...
Read MoreBLKB expanding support for startups
BLKB offers particularly promising SMEs and startups financial support within the framework of the “100 fürs Baselbiet” program. These companies...
Read MoreCombatting the rise of antimicrobial resistance
Antimicrobial resistance (AMR) is a growing global threat that, without intervention, could lead to as many as 10 million deaths...
Read MoreAMR Action Fund invests in new antibiotics developed by BioVersys
The AMR Action Fund has made its first European investment in BioVersys, which is headquartered at Tech Park Basel. The...
Read MoreInvestors give Resistell 8.5 million Swiss francs
Resistell AG has secured 8.5 million Swiss francs in the first part of its series B funding round. The biotechnology...
Read MoreBSI integrating AI from Parashift in banking software
Parashift, the specialist in the area of smart document processing on the basis of Artificial Intelligence (AI), has entered into...
Read MoreUptownBasel joins IBM Quantum Network
UptownBasel is partnering with IBM. The emerging competence center for Industry 4.0 will provide its partners with the IBM Quantum...
Read MoreSouth Korean pharma firms show interest in the Basel Area
Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...
Read More